Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, TRI, FDA

Applied Spectral Imaging Launches Two New Products for the Digital Pathology Market


CARLSBAD, California, Oct. 4, 2017 /PRNewswire/ -- Applied Spectral Imaging (ASI), a global leader in computer-assisted biomedical imaging, announced today the launch of PathFusiontm and HiPath Protm, innovative Brightfield and FISH imaging & analysis solutions for pathology. ASI will unveil the new products at the upcoming CAP2017 meeting in Maryland, October 8-10, 2017.

PathFusiontm by ASI for advanced digital pathology

The PathFusion system is a cutting-edge workflow solution, bridging the gap between Brightfield pathology and FISH. Combining microscope-based Whole Slide Imaging, industry-leading Tissue FISH applications and revolutionary digital tissue matching of FISH with H&E/IHC samples, it provides accurate and validated analysis for higher diagnostic confidence. Powered by GenASIs, PathFusion supports a wide range of sample types, IHC antibodies and FISH probes, and features modern digital workflows that increase laboratory productivity and improve FTE savings.

HiPath Pro is a unique Brightfield imaging & analysis system for a variety of histopathology needs, including Whole Slide Imaging of H&E/IHC samples and Quantitative IHC Scoring of membrane and nuclear stains. Through exceptional image quality and precise computer-assisted analysis, it provides uncompromising results standardization, in addition to streamlining communication and simplifying sharing processes. The HiPath Pro manual configuration is FDA cleared for IHC Family HER2/neu, ER, PR and Ki-67.

"We are excited to introduce these new breakthrough technologies, demonstrating once again our relentless commitment to advancing patient diagnostics", said Limor Shiposh, CEO of ASI. "PathFusion and HiPath Pro, both powered by our proprietary GenASIs algorithms, address the most pressing needs of modern pathology laboratories: digital workflows that increase productivity, labor efficiencies, data accessibility and above all, standardized results through accurate, consistent analysis."

Visit the ASI booth #805 at the CAP2017 meeting to learn more.

About ASI
ASI is a global leader in the development of biomedical imaging solutions, supporting fluorescent, Brightfield and spectral image-acquisition, for the Pathology and Cytogenetics markets.

HiPath Protm and PathFusiontm, powered by GenASIstm, are automated imaging platforms that provide advanced diagnostic aids for pathologists, with reproducible and standardized results. ASI platforms support manual and automatic scanning for a wide range of workflows and applications, to best suit the needs, size and budget of any laboratory. 

ASI's applications are FDA cleared for BandView, FISHView, CEP XY, UroVysion, ALK, HER2/neu FISH and IHC Family for: HER2, ER, PR and Ki67.

ASI serves clinical laboratories, life science companies and research institutions in over 50 countries.

www.appliedspectralimaging.com/digitalpathology

For More Information Please Contact 
Applied Spectral Imaging 
Phone: +1 (760) 929-2840
E-mail: [email protected]

 

SOURCE Applied Spectral Imaging (ASI)


These press releases may also interest you

at 12:15
ResBiotic Nutrition, Inc. (ResBiotic), the pioneering physician-developed pre/probiotic wellness scale-up, proudly announces the appointments of Stefany Nieto as Vice President of Operations and Brittany Zenner as Director of Marketing. Nieto is a...

at 12:06
Maid Sailors Cleaning Service has joined forces with Cleaning for a Reason, a non-profit organization offering free house cleaning services to cancer patients across the United States and Canada....

at 12:05
Terragia Biofuel, a technology startup aiming to drive the next generation of biofuels, today announced it has raised a $6 million seed round led by Engine Ventures and Energy Impact Partners (EIP). The company will use the capital to commercialize...

at 12:05
Float, the marketplace moving all the care that doesn't need a hospital to the home, today announced $10 million in Series A funding led by Canvas Ventures, whose General Partner Mike Ghaffary has joined Float's board, with participation from Wave...

at 12:00
V-Wave today announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American College of Cardiology's (ACC) Annual Scientific Session & Expo taking place April 6-8 in Atlanta. RELIEVE-HF is a randomized, double-blind,...

at 12:00
Critical Path Institute's (C-Path) Duchenne Regulatory Science Consortium (D-RSC) is excited to announce the launch of a groundbreaking model-based Clinical Trial Simulator (CTS), specifically designed to improve design of efficacy studies for...



News published on and distributed by: